A RCT Study of ERAS in Infants With Choledochal Cyst

Sponsor
Nanjing Children's Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05770739
Collaborator
(none)
90
1
2
36
2.5

Study Details

Study Description

Brief Summary

Recently, with reference to the successful experience of accelerated rehabilitation surgery in the field of adult surgery, the investigators have conducted studies on ERAS in pediatric and even infant cholangiectasia surgery to discuss its feasibility and safety. The results showed that some items of ERAS could be safely applied in perioperative management of CBD, and could reduce traumatic stress and promote postoperative recovery. Therefore, the investigators assumed that the ERAS protocols could be safely applied in the treatment of CBD in children and even infants, reducing traumatic stress in children with CBD, promoting postoperative rehabilitation, reducing complications and hospitalization time, reducing hospitalization costs, and saving medical resources.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Perioperative accelerated rehabilitation surgical measures
  • Behavioral: Traditional treatment
N/A

Detailed Description

  1. Optimize preoperative, intraoperative and postoperative perioperative management by learning from the successful experience of accelerated rehabilitation surgery model in other fields.

For example: necessary and sufficient preoperative education of children and guardians; short fasting before surgery; oral carbohydrate at 2h before surgery; breast feeding at 4h before surgery (formula feeding at 6h before surgery); improved intestinal preparation; irregular placement of nasogastric tube; the use of general anesthesia plus epidural or sacral block anesthesia during surgery; attention to the whole process of heat preservation; strict control of infusion volume; and selection of minimally invasive hands Methods of operation; early postoperative activity, multi-mode analgesia, etc.

  1. According to the pathophysiological characteristics of infants with cholangiectasia, several aspects were studied: minimally invasive surgery;promote gastrointestinal motor function recovery;develop principles and plans for early postoperative feeding;Rational placement of abdominal drainage tube; precise choice of anesthesia method, etc.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Application of Enhanced Recovery After Surgery During the Perioperative Period in Infants With Choledochal Cyst- a Multi-center Randomized Clinical Trial
Actual Study Start Date :
Jan 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: ERAS group

To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period

Behavioral: Perioperative accelerated rehabilitation surgical measures
To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period

Other: placebo group

In this gruop,Children with cholangiectasia were given traditional perioperative treatment

Behavioral: Traditional treatment
To provide traditional perioperative treatment for children with cholangiectasia

Outcome Measures

Primary Outcome Measures

  1. postoperative length of stay [through study completion, an average of 1 year]

    To record the postoperative length of stay

Secondary Outcome Measures

  1. gastrointestinal functional recovery [through study completion, an average of 1 month]

    To record the time of first exhaust and defecation and the time to return to full oral diet

  2. Gastrointestinal decompression tube indwelling time [through study completion, an average of 1 month]

    To calculate the indwelling time of Gastrointestinal decompression tube after surgery

  3. Peritoneal drainage tube indwelling time [through study completion, an average of 1 month]

    To calculate the indwelling time of Peritoneal drainage tube

  4. Blood cortisol level [24 hours after surgery]

    To test the consentration of cortisol in blood

  5. IL-6 level [24 hours after surgery]

    To test the consentration of IL-6 in blood

  6. IL-10 level [24 hours after surgery]

    To test the consentration of IL-10 in blood

  7. C-reactive protein (CRP) [24 hours after surgery]

    To test the consentration of CRP in blood

  8. complication rate [one month after surgery]

    to observe postoperative pulmonary infection, infection of incision, baby, abdominal cavity infection and the occurrence of complications such as anastomotic fistula, cholangitis.

  9. Hospitalization expenses [through study completion, an average of 1 month]

    the hospitalization cost of the child

  10. Parents satisfaction score [through study completion, an average of 1 month]

    To investigate the "Parents satisfaction score scale" (minimum=0, maximun=100); the higher scores mean a better outcome.

  11. 30-day readmission rate [one month after surgery]

    To record the 30-day readmission rate after surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Day to 12 Months
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Infants aged 0-12 months

  • According to the clinical manifestations and preoperative imaging examination, the children admitted to hospital were diagnosed with choledochal cyst

  • The legal guardian of the child signs the Informed Consent

Exclusion Criteria:
  • Have potentially life-threatening diseases of various organ systems

  • Preoperatively associated with other diseases that interfere with the treatment process of the child

  • Caroli's disease was diagnosed

  • Any other condition that the investigator deems unsuitable for participation in the trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Children's Hospital of Nanjing Medical University Nanjing Jiangsu China 210008

Sponsors and Collaborators

  • Nanjing Children's Hospital

Investigators

  • Principal Investigator: Xiaofeng Lv, Master, Children's Hospital of Nanjing Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Weibing Tang, professor, Nanjing Children's Hospital
ClinicalTrials.gov Identifier:
NCT05770739
Other Study ID Numbers:
  • 202204038-1
First Posted:
Mar 15, 2023
Last Update Posted:
Mar 15, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2023